QUANTM Irradiation System™ Earns CE Mark Approval
ARTMS Products today announced it received CE marking approval for its first-in-class, advanced technology QUANTM Irradiation System™ for producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons. Cyclotron facilities are constantly facing higher isotope costs and poor supply availability. Now, with CE marking, ARTMS’ QUANTM Irradiation System™ will help ease these issues.
"CE marking is an important milestone for ARTMS," remarked Dr. Kaley Wilson, CEO of ARTMS Products. "There is a huge opportunity in providing a cost effective and secured supply of radioisotopes to hospitals and research institutions. ARTMS provides a more economical, environmentally safe and secured supply of important radioisotopes than reactor-based sources. Now, with CE marking approval, ARTMS can be readily integrated in a standardized fashion into existing and emerging facilities which ultimately leads to improved patient access and care across Europe."
Giving Cyclotron Facilities More Control Over the Supply of Medical Isotopes
Unlike traditional reactor and generator production methods, which are growing increasingly more expensive and cannot consistently supply user requirements, the ARTMS QUANTM Irradiation System™ combines both local production control and a cost-effective, easy-to-use solid target system for production of radioisotopes on medical cyclotrons. Medical radioisotopes are used in the field of nuclear medicine on a daily basis for both medical diagnostic imaging and therapy, particularly in the fields of oncology, cardiology and neurology.
The ARTMS QUANTM Irradiation System™ is currently available for most OEM cyclotron systems and has been installed and is operating in a number of countries.
About ARTMS Products
Based in Vancouver, British Columbia, ARTMS Products Inc. is a leader in the development of novel technologies and products which enable the production of the world’s most-used diagnostic imaging isotope, technetium-99m (Tc-99m), using local, hospital-based medical cyclotrons. ARTMS holds the exclusive global commercialization rights to award-winning and proprietary Canadian inventions which address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.
ARTMS Products Inc.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
POSIFLEX-GROUP24.5.2019 03:02:05 CEST | Pressemeddelelse
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 2019
CA-ANDERSEN-TAX23.5.2019 22:49:12 CEST | Pressemeddelelse
Andersen Global udvider lokaliteter i Storbritannien
VA-CTA23.5.2019 22:02:10 CEST | Pressemeddelelse
Audi China President Thomas Owsianski to Keynote at CES Asia 2019
VA-ITECHLAW23.5.2019 21:13:07 CEST | Pressemeddelelse
ITechLaw Publishes New Book and Opens Global Public Comment Period on Draft Principles for Responsible Artificial Intelligence
KUMULUS-VAPE23.5.2019 18:51:10 CEST | Pressemeddelelse
Kumulus Vape, the 100% Online E-Cigarette Specialist, Goes Public
MINDBREEZE23.5.2019 15:13:11 CEST | Pressemeddelelse
Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum